{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:55:55Z","timestamp":1794621355288,"version":"4.9.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Administration of Traditional Chinese Medicine - Zhejiang Provincial Administration of Traditional Chinese Medicine Joint Construction Technology Plan","award":["GZY-ZJ-KJ-23092"],"award-info":[{"award-number":["GZY-ZJ-KJ-23092"]}]},{"name":"Zhejiang Provincial Natural Science Foundation of China under Grant","award":["LY23H290004"],"award-info":[{"award-number":["LY23H290004"]}]},{"DOI":"10.13039\/100007834","name":"Ningbo Natural Science Foundation","doi-asserted-by":"crossref","award":["2022J242"],"award-info":[{"award-number":["2022J242"]}],"id":[{"id":"10.13039\/100007834","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Zhejiang Province Traditional Chinese Medicine Science and Technology Plan","award":["2022ZB332"],"award-info":[{"award-number":["2022ZB332"]}]},{"name":"the Project of NINGBO Leading Medical & Health Discipline","award":["2022Z01"],"award-info":[{"award-number":["2022Z01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02373-1","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T12:04:42Z","timestamp":1740485082000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Risk factor analysis and predictive model construction of lean MAFLD: a cross-sectional study of a health check-up population in China"],"prefix":"10.1186","volume":"30","author":[{"given":"Ruya","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caicai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suwen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"issue":"7","key":"2373_CR1","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J, International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999\u20132014.","journal-title":"Gastroenterology"},{"issue":"6","key":"2373_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"PB Duell","year":"2022","unstructured":"Duell PB, Welty FK, Miller M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American heart association. Arterioscler Thromb Vasc Biol. 2022;42(6):168\u201385.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"2373_CR3","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","volume":"65","author":"N Katsiki","year":"2016","unstructured":"Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism. 2016;65(8):1109\u201323.","journal-title":"Metabolism"},{"issue":"4","key":"2373_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41581-021-00519-y","volume":"18","author":"TY Wang","year":"2022","unstructured":"Wang TY, Wang RF, Bu ZY, et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat Rev Nephrol. 2022;18(4):259\u201368.","journal-title":"Nat Rev Nephrol"},{"issue":"9","key":"2373_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851\u201361.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"2373_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384.","journal-title":"Hepatology"},{"issue":"6","key":"2373_CR7","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672\u201382.","journal-title":"Hepatology"},{"issue":"4","key":"2373_CR8","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/hep.30702","volume":"70","author":"F Zhou","year":"2019","unstructured":"Zhou F, Zhou J, Wang W, Zhang XJ, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis. Hepatology. 2019;70(4):1119\u201333.","journal-title":"Hepatology"},{"issue":"5","key":"2373_CR9","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389\u201398.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10290","key":"2373_CR10","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW-S, Rinella M. Non-alcoholic fatty liver disease. The Lancet. 2021;397(10290):2212\u201324.","journal-title":"The Lancet"},{"issue":"4","key":"2373_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2020","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2020;18(4):223\u201338.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2373_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","volume":"92","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism. 2019;92:82\u201397.","journal-title":"Metabolism"},{"issue":"1","key":"2373_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","volume":"8","author":"J Quek","year":"2023","unstructured":"Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20\u201330.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"2373_CR14","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.cgh.2022.06.029","volume":"21","author":"A Tang","year":"2023","unstructured":"Tang A, Ng CH, Phang PH, Muthiah M, Noureddin M, et al. Comparative burden of metabolic dysfunction in lean NAFLD vs non-lean NAFLD\u2014a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21(7):1750\u201360.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2373_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110699","volume":"200","author":"Y Gao","year":"2023","unstructured":"Gao Y, Zhao T, Song S, et al. Lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes mellitus: a literature review and meta-analysis. Diabetes Res Clin Pract. 2023;200: 110699.","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"2373_CR16","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1111\/jgh.15353","volume":"36","author":"M Ahadi","year":"2020","unstructured":"Ahadi M, Molooghi K, Masoudifar N, et al. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroen Hepatol. 2020;36(6):1497\u2013507.","journal-title":"J Gastroen Hepatol"},{"key":"2373_CR17","doi-asserted-by":"publisher","first-page":"1038475","DOI":"10.3389\/fmed.2022.1038475","volume":"9","author":"N Gao","year":"2022","unstructured":"Gao N, Deng J, Wang J, et al. The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease. Front Med. 2022;9:1038475.","journal-title":"Front Med"},{"key":"2373_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03351-5","author":"S Huang","year":"2023","unstructured":"Huang S, Bao Y, Zhang N, et al. Long-term outcomes in lean and non-lean NAFLD patients: a systematic review and meta-analysis. Endocrine. 2023. https:\/\/doi.org\/10.1007\/s12020-023-03351-5.","journal-title":"Endocrine"},{"issue":"8","key":"2373_CR19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739\u201352.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl","key":"2373_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3350\/cmh.2022.0350","volume":"29","author":"W-K Chan","year":"2023","unstructured":"Chan W-K. Comparison between obese and non-obese nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):58\u201367.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"2373_CR21","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1038\/s41467-021-27309-1","volume":"12","author":"Y Peng","year":"2021","unstructured":"Peng Y, Zeng Q, Wan L, et al. GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity. Nat Commun. 2021;12(1):7004.","journal-title":"Nat Commun"},{"issue":"1","key":"2373_CR22","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.1038\/s41467-020-18754-5","volume":"11","author":"G Lee","year":"2020","unstructured":"Lee G, You HJ, Bajaj JS, et al. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nat Commun. 2020;11(1):4982.","journal-title":"Nat Commun"},{"issue":"15","key":"2373_CR23","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.3390\/jcm11154260","volume":"11","author":"ZA Razouki","year":"2022","unstructured":"Razouki ZA, Zhang X, Hwang JP, et al. Clinical factors associated with non-obese nonalcoholic fatty liver disease detected among US adults in the NHANES 2017\u20132018. J Clin Med. 2022;11(15):4260.","journal-title":"J Clin Med"},{"issue":"9","key":"2373_CR24","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/hepr.13543","volume":"50","author":"T Shida","year":"2020","unstructured":"Shida T, Oshida N, Suzuki H, et al. Clinical and anthropometric characteristics of non-obese non-alcoholic fatty liver disease subjects in Japan. Hepatol Res. 2020;50(9):1032\u201346.","journal-title":"Hepatol Res"},{"issue":"5","key":"2373_CR25","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1007\/s12072-024-10701-6","volume":"18","author":"M Alarabi","year":"2024","unstructured":"Alarabi M, Pan Z, Romero-G\u00f3mez M, et al. Telomere length and mortality in lean MAFLD: the other face of metabolic adaptation. Hepatol Int. 2024;18(5):1448\u201358.","journal-title":"Hepatol Int"},{"issue":"4","key":"2373_CR26","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1016\/S1470-2045(14)71116-7","volume":"16","author":"VP Balachandran","year":"2015","unstructured":"Balachandran VP, Gonen M, Smith JJ, et al. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173\u201380.","journal-title":"Lancet Oncol"},{"issue":"7","key":"2373_CR27","first-page":"4505","volume":"14","author":"X Cai","year":"2022","unstructured":"Cai X, Wang M, Liu S, et al. Establishment and validation of a nomogram that predicts the risk of type 2 diabetes in obese patients with non-alcoholic fatty liver disease: a longitudinal observational study. Am J Transl Res. 2022;14(7):4505\u201314.","journal-title":"Am J Transl Res"},{"key":"2373_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5527460","author":"X Cai","year":"2021","unstructured":"Cai X, Zhu Q, Cao Y, et al. A prediction model based on noninvasive indicators to predict the 8-year incidence of type 2 diabetes in patients with nonalcoholic fatty liver disease: a population-based retrospective cohort study. Biomed Res Int. 2021. https:\/\/doi.org\/10.1155\/2021\/5527460.","journal-title":"Biomed Res Int"},{"issue":"6","key":"2373_CR29","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sarin SK, Wong VW-S, et al. The Asian Pacific Association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hep Intl. 2020;14(6):889\u2013919.","journal-title":"Hep Intl"},{"issue":"10","key":"2373_CR30","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.3390\/biomedicines9101346","volume":"9","author":"MS Kuchay","year":"2021","unstructured":"Kuchay MS, Mart\u00ednez-Montoro JI, Choudhary NS, et al. Non-alcoholic fatty liver disease in lean and non-obese individuals: current and future challenges. Biomedicines. 2021;9(10):1346.","journal-title":"Biomedicines"},{"issue":"10","key":"2373_CR31","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41575-022-00635-5","volume":"19","author":"M Eslam","year":"2022","unstructured":"Eslam M, El-Serag HB, Francque S, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19(10):638\u201351.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"2373_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jacc.2016.03.597","volume":"68","author":"E Levelt","year":"2016","unstructured":"Levelt E, Pavlides M, Banerjee R, et al. Ectopic and visceral fat deposition in lean and obese patients with type 2 diabetes. J Am Coll Cardiol. 2016;68(1):53\u201363.","journal-title":"J Am Coll Cardiol"},{"key":"2373_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101143","volume":"50","author":"KK Bence","year":"2021","unstructured":"Bence KK, Birnbaum MJ. Metabolic drivers of non-alcoholic fatty liver disease. Mol Metab. 2021;50: 101143.","journal-title":"Mol Metab"},{"issue":"2","key":"2373_CR34","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1046\/j.1440-1746.2003.02989.x","volume":"18","author":"GC Farrell","year":"2003","unstructured":"Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol. 2003;18(2):124\u201338.","journal-title":"J Gastroenterol Hepatol"},{"key":"2373_CR35","doi-asserted-by":"publisher","first-page":"154955","DOI":"10.1016\/j.metabol.2021.154955","volume":"127","author":"Z Liu","year":"2022","unstructured":"Liu Z, Lin C, Suo C, et al. Metabolic dysfunction\u2013associated fatty liver disease and the risk of 24 specific cancers. Metabolism. 2022;127:154955.","journal-title":"Metabolism"},{"issue":"2","key":"2373_CR36","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.juro.2009.09.071","volume":"183","author":"I Tanaka","year":"2010","unstructured":"Tanaka I, Nagase K, Tanase K, et al. Improvement in neurogenic detrusor overactivity by peripheral C fiber\u2019s suppression with cyclooxygenase inhibitors. J Urol. 2010;183(2):786\u201392.","journal-title":"J Urol"},{"issue":"21","key":"2373_CR37","doi-asserted-by":"publisher","first-page":"11629","DOI":"10.3390\/ijms222111629","volume":"22","author":"J Guti\u00e9rrez-Cuevas","year":"2021","unstructured":"Guti\u00e9rrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases. Int J Mol Sci. 2021;22(21):11629.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2373_CR38","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.cgh.2021.07.016","volume":"20","author":"OT Ahmed","year":"2022","unstructured":"Ahmed OT, Gidener T, Mara KC, et al. Natural history of nonalcoholic fatty liver disease with normal body mass index: a population-based study. Clin Gastroenterol H. 2022;20(6):1374-1381.e1376.","journal-title":"Clin Gastroenterol H"},{"issue":"5","key":"2373_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11892-021-01383-7","volume":"21","author":"C Caussy","year":"2021","unstructured":"Caussy C, Aubin A, Loomba R. The relationship between type 2 diabetes, NAFLD, and cardiovascular risk. Curr Diabetes Rep. 2021;21(5):1.","journal-title":"Curr Diabetes Rep"},{"issue":"7","key":"2373_CR40","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.tem.2021.04.008","volume":"32","author":"S Lim","year":"2021","unstructured":"Lim S, Kim J-W, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2021;32(7):500\u201314.","journal-title":"Trends Endocrinol Metab"},{"issue":"8","key":"2373_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238388","volume":"15","author":"JM Peterson","year":"2020","unstructured":"Peterson JM, Sogabe M, Okahisa T, et al. Differences among patients with and without nonalcoholic fatty liver disease having elevated alanine aminotransferase levels at various stages of metabolic syndrome. PLoS ONE. 2020;15(8): e0238388.","journal-title":"PLoS ONE"},{"key":"2373_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154911","volume":"126","author":"EX-X Tan","year":"2022","unstructured":"Tan EX-X, Lee JW-J, Jumat NH, et al. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. Metabolism. 2022;126: 154911.","journal-title":"Metabolism"},{"issue":"1","key":"2373_CR43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3350\/cmh.2021.0338","volume":"28","author":"SM Lee","year":"2022","unstructured":"Lee SM, Kim W. Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: ready for prime time? Clin Mol Hepatol. 2022;28(1):47\u20139.","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"2373_CR44","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jhep.2015.11.030","volume":"64","author":"RH Westbrook","year":"2016","unstructured":"Westbrook RH, Dusheiko G, Williamson C. Pregnancy and liver disease. J Hepatol. 2016;64(4):933\u201345.","journal-title":"J Hepatol"},{"issue":"11","key":"2373_CR45","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1016\/j.cgh.2021.11.007","volume":"20","author":"SM Lee","year":"2022","unstructured":"Lee SM, Jung YM, Choi ES, et al. Metabolic dysfunction-associated fatty liver disease and subsequent development of adverse pregnancy outcomes. Clin Gastroenterol H. 2022;20(11):2542\u201350.","journal-title":"Clin Gastroenterol H"},{"issue":"18","key":"2373_CR46","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","volume":"75","author":"DH Ipsen","year":"2018","unstructured":"Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75(18):3313\u201327.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"2373_CR47","doi-asserted-by":"publisher","first-page":"15691","DOI":"10.1038\/ncomms15691","volume":"8","author":"M Ogrodnik","year":"2017","unstructured":"Ogrodnik M, Miwa S, Tchkonia T, et al. Cellular senescence drives age-dependent hepatic steatosis. Nat Commun. 2017;8(1):15691.","journal-title":"Nat Commun"},{"issue":"1","key":"2373_CR48","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13293-022-00475-7","volume":"13","author":"S Fresneda","year":"2022","unstructured":"Fresneda S, Abbate M, Busquets-Cort\u00e9s C, et al. Sex and age differences in the association of fatty liver index-defined non-alcoholic fatty liver disease with cardiometabolic risk factors: a cross-sectional study. Biol Sex Diff. 2022;13(1):64.","journal-title":"Biol Sex Diff"},{"issue":"9","key":"2373_CR49","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1089\/ars.2021.0044","volume":"35","author":"A Mor\u00e1n-Costoya","year":"2021","unstructured":"Mor\u00e1n-Costoya A, Proenza AM, Gianotti M, et al. Sex differences in nonalcoholic fatty liver disease: estrogen influence on the liver-adipose tissue crosstalk. Antioxid Redox Signal. 2021;35(9):753\u201374.","journal-title":"Antioxid Redox Signal"},{"issue":"5","key":"2373_CR50","doi-asserted-by":"publisher","first-page":"537","DOI":"10.5009\/gnl19236","volume":"14","author":"M Tobari","year":"2020","unstructured":"Tobari M, Hashimoto E. Characteristic features of nonalcoholic fatty liver disease in Japan with a focus on the roles of age, sex and body mass index. Gut Liver. 2020;14(5):537\u201345.","journal-title":"Gut Liver"},{"issue":"4","key":"2373_CR51","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/hep.30626","volume":"70","author":"A Lonardo","year":"2019","unstructured":"Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70(4):1457\u201369.","journal-title":"Hepatology"},{"key":"2373_CR52","doi-asserted-by":"publisher","first-page":"154183","DOI":"10.1016\/j.metabol.2020.154183","volume":"111","author":"S Kechagias","year":"2020","unstructured":"Kechagias S, Nasr P, Blomdahl J, et al. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism. 2020;111:154183.","journal-title":"Metabolism"},{"issue":"8","key":"2373_CR53","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/hep4.1534","volume":"4","author":"P Golabi","year":"2020","unstructured":"Golabi P, Paik JM, Arshad T, et al. Mortality of NAFLD according to the body composition and presence of metabolic abnormalities. Hepatol Commun. 2020;4(8):1136\u201348.","journal-title":"Hepatol Commun"},{"issue":"1","key":"2373_CR54","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s12072-022-10436-2","volume":"17","author":"AD Dao","year":"2022","unstructured":"Dao AD, Nguyen VH, Ito T, et al. Prevalence, characteristics, and mortality outcomes of obese and nonobese MAFLD in the United States. Hep Intl. 2022;17(1):225\u201336.","journal-title":"Hep Intl"},{"issue":"10","key":"2373_CR55","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.dld.2019.02.019","volume":"51","author":"C Shao","year":"2019","unstructured":"Shao C, Ye J, Li F, et al. Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease. Digest Liver Dis. 2019;51(10):1392\u20139.","journal-title":"Digest Liver Dis"},{"issue":"11","key":"2373_CR56","first-page":"2600","volume":"37","author":"D Jiang","year":"2021","unstructured":"Jiang D, Zhiyi H, Cailan X, et al. Analysis of the prevalence and influencing factors of non-obese fatty liver. J Clin Hepatobil Dis. 2021;37(11):2600\u20134.","journal-title":"J Clin Hepatobil Dis"},{"issue":"19","key":"2373_CR57","first-page":"142","volume":"14","author":"F Miaomiao","year":"2022","unstructured":"Miaomiao F. Research progress of lean nonalcoholic fatty liver disease. Chin Med Clin Res. 2022;14(19):142\u20135.","journal-title":"Chin Med Clin Res"},{"issue":"1","key":"2373_CR58","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12933-023-01906-4","volume":"22","author":"S Liang","year":"2023","unstructured":"Liang S, Wang C, Zhang J, et al. Triglyceride-glucose index and coronary artery disease: a systematic review and meta-analysis of risk, severity, and prognosis. Cardiovasc Diabetol. 2023;22(1):170.","journal-title":"Cardiovasc Diabetol"},{"key":"2373_CR59","doi-asserted-by":"publisher","first-page":"1035105","DOI":"10.3389\/fcvm.2022.1035105","volume":"9","author":"IF Muhammad","year":"2023","unstructured":"Muhammad IF, Bao X, Nilsson PM, et al. Triglyceride-glucose (TyG) index is a predictor of arterial stiffness, incidence of diabetes, cardiovascular disease, and all-cause and cardiovascular mortality: a longitudinal two-cohort analysis. Front Cardiovasc Med. 2023;9:1035105.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"2373_CR60","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12933-022-01732-0","volume":"22","author":"Y Yang","year":"2023","unstructured":"Yang Y, Huang X, Wang Y, et al. The impact of triglyceride-glucose index on ischemic stroke: a systematic review and meta-analysis. Cardiovasc Diabetol. 2023;22(1):2.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2373_CR61","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12933-024-02392-y","volume":"23","author":"SS Nayak","year":"2024","unstructured":"Nayak SS, Kuriyakose D, Polisetty LD, et al. Diagnostic and prognostic value of triglyceride glucose index: a comprehensive evaluation of meta-analysis. Cardiovasc Diabetol. 2024;23(1):310.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"2373_CR62","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jcmgh.2021.12.003","volume":"13","author":"F-Z Xin","year":"2022","unstructured":"Xin F-Z, Zhao Z-H, Liu X-L, et al. Escherichia fergusonii promotes nonobese nonalcoholic fatty liver disease by interfering with host hepatic lipid metabolism through its own msRNA 23487. Cell Mol Gastroenterol Hepatol. 2022;13(3):827\u201341.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"2373_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-020-00917-2","volume":"12","author":"D Buzova","year":"2020","unstructured":"Buzova D, Maugeri A, Liguori A, et al. Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD). Clin Epigenetics. 2020;12(1):1.","journal-title":"Clin Epigenetics"},{"issue":"4","key":"2373_CR64","doi-asserted-by":"publisher","first-page":"173","DOI":"10.21037\/atm-22-6620","volume":"11","author":"N Shen","year":"2023","unstructured":"Shen N, Tang L, Qian Y, et al. Serum miR-4488 as a potential biomarker of lean nonalcoholic fatty liver disease. Ann Transl Med. 2023;11(4):173\u2013173.","journal-title":"Ann Transl Med"},{"key":"2373_CR65","doi-asserted-by":"publisher","first-page":"155583","DOI":"10.1016\/j.metabol.2023.155583","volume":"144","author":"J Alharthi","year":"2023","unstructured":"Alharthi J, Pan Z, Gloss BS, et al. Loss of metabolic adaptation in lean MAFLD is driven by endotoxemia leading to epigenetic reprogramming. Metabolism. 2023;144:155583.","journal-title":"Metabolism"},{"issue":"1","key":"2373_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1507\/endocrj.EJ18-0435","volume":"66","author":"Y Tamura","year":"2019","unstructured":"Tamura Y. Ectopic fat, insulin resistance and metabolic disease in non-obese Asians: investigating metabolic gradation. Endocr J. 2019;66(1):1\u20139.","journal-title":"Endocr J"},{"issue":"4","key":"2373_CR67","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/diagnostics13040614","volume":"13","author":"F Radu","year":"2023","unstructured":"Radu F, Potcovaru C-G, Salmen T, et al. The link between NAFLD and metabolic syndrome. Diagnostics. 2023;13(4):614.","journal-title":"Diagnostics"},{"issue":"3","key":"2373_CR68","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.numecd.2021.11.017","volume":"32","author":"D-H Son","year":"2022","unstructured":"Son D-H, Lee HS, Lee Y-J, et al. Comparison of triglyceride-glucose index and HOMA-IR for predicting prevalence and incidence of metabolic syndrome. Nutr Metab Cardiovasc Dis. 2022;32(3):596\u2013604.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"8","key":"2373_CR69","doi-asserted-by":"publisher","first-page":"102581","DOI":"10.1016\/j.dsx.2022.102581","volume":"16","author":"DL Tahapary","year":"2022","unstructured":"Tahapary DL, Pratisthita LB, Fitri NA, et al. Challenges in the diagnosis of insulin resistance: focusing on the role of HOMA-IR and tryglyceride\/glucose index. Diabetes Metab Syndr Clin Res Rev. 2022;16(8):102581.","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"issue":"4","key":"2373_CR70","doi-asserted-by":"publisher","first-page":"101345","DOI":"10.1016\/j.diabet.2022.101345","volume":"48","author":"B Rivi\u00e8re","year":"2022","unstructured":"Rivi\u00e8re B, Jaussent A, Macioce V, et al. The triglycerides and glucose (TyG) index: a new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients. Diabetes Metab. 2022;48(4):101345.","journal-title":"Diabetes Metab"},{"issue":"1","key":"2373_CR71","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12933-022-01548-y","volume":"21","author":"J Zhao","year":"2022","unstructured":"Zhao J, Fan H, Wang T, et al. TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients. Cardiovasc Diabetol. 2022;21(1):123.","journal-title":"Cardiovasc Diabetol"},{"key":"2373_CR72","first-page":"3167","volume":"15","author":"R Zhang","year":"2022","unstructured":"Zhang R, Guan Q, Zhang M, et al. Association between triglyceride-glucose index and risk of metabolic dysfunction-associated fatty liver disease: a cohort study diabetes. Metab Syndr Obes Targ Ther. 2022;15:3167\u201379.","journal-title":"Metab Syndr Obes Targ Ther"},{"key":"2373_CR73","doi-asserted-by":"publisher","first-page":"1124019","DOI":"10.3389\/fendo.2023.1124019","volume":"14","author":"V Furdela","year":"2023","unstructured":"Furdela V, Pavlyshyn H, Shulhai A-M, et al. Triglyceride glucose index, pediatric NAFLD fibrosis index, and triglyceride-to-high-density lipoprotein cholesterol ratio are the most predictive markers of the metabolically unhealthy phenotype in overweight\/obese adolescent boys. Front Endocrinol. 2023;14:1124019.","journal-title":"Front Endocrinol"},{"key":"2373_CR74","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8852198","author":"X Cai","year":"2020","unstructured":"Cai X, Aierken X, Ahmat A, et al. A nomogram model based on noninvasive bioindicators to predict 3-year risk of nonalcoholic fatty liver in nonobese mainland chinese: a prospective cohort study. Biomed Res Int. 2020. https:\/\/doi.org\/10.1155\/2020\/8852198.","journal-title":"Biomed Res Int"},{"key":"2373_CR75","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.2147\/IJGM.S319759","volume":"14","author":"L Ji","year":"2021","unstructured":"Ji L, Cai X, Bai Y, Li T. Application of a novel prediction model for predicting 2-year risk of non-alcoholic fatty liver disease in the non-obese population with normal blood lipid levels: a large prospective cohort study from China. Int J Gen Med. 2021;14:2909\u201322.","journal-title":"Int J Gen Med"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02373-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02373-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02373-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T13:26:07Z","timestamp":1740489967000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02373-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2373"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02373-1","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol complied with the principles of the Declaration of Helsinki. The Ethics Committee of the First Affiliated Yuyao People's Hospital approved this study (2024\u201301-001), confirming it as a retrospective study that meets the ethical requirements for waiver of informed consent. All data were collected in an electronic medical record system. All methods were performed in accordance with the relevant guidelines and regulations. There have been several researchers to check the accuracy and completeness of the data to avoid information bias. In addition, researchers anonymise or de-identify patient data to reduce the risk of data breaches.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}